Clinical Trials
6 trialsNCT03631199 2026-02-25
CANOPY-1
Novartis
Phase 3 Terminated
NCT03742349 2025-05-18
Study of Safety and Efficacy of Novel Immunotherapy Combinations in Patients With Triple Negative Breast Cancer (TNBC).
Novartis
Phase 1 Terminated
NCT03447769 2024-10-09
Canopy-A
Novartis
Phase 3 Terminated
NCT03968419 2024-06-20
CANOPY-N
Novartis
Phase 2 Terminated
NCT03626545 2023-08-21
CANOPY-2
Novartis
Phase 3 Terminated
NCT03064854 2022-08-15
PDR001 in Combination With Platinum-doublet Chemotherapy and Other Immunology Agents in PD-L1 Unselected, Metastatic NSCLC Patients
Novartis
Phase 1 Terminated